Reply to rituxan is not associated with Stevens-Johnson syndrome

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 807-807

  Parise, L ^a   Kahle, J ^a   Schlaak, M ^a   Mauch, C ^a   Kurschat, P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISOLONE; PROTEIN KINASE ZAP 70; RITUXIMAB;

ADULT; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FATIGUE; FEVER; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LETTER; MACULOPAPULAR RASH; MALE; PRIORITY JOURNAL; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; STOMATITIS;

ANTIBODIES, MONOCLONAL; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; STEVENS-JOHNSON SYNDROME;

EID: 84857554735     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr629     Document Type: Letter

References (4)

1. Henning JS, Firoz BF. Rituxan is not associated with Stevens Johnson syndrome. Ann Oncol 2011; 22: 1463-1464.
2. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-1950.
3. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14: 1792.
4. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology 2001; 203: 83-84.